解放军医学院学报2024，Vol.45Issue(7)：746-752,7.DOI:10.12435/j.issn.2095-5227.2024.056
CD44异构体在HER2 3+阳性乳腺癌中的表达及其与预后的关系
Heterogeneous expressions of CD44 variant isoforms in HER2 3+positive breast cancer and its prognosis
摘要
Abstract
Background CD44 variant isoforms are involved in the progression of breast cancer.However,the clinicopathological features and prognostic risk of CD44 variant isoforms(v6 and v8-10)in HER2 3+positive breast cancer are still unclear.Objective To investigate the expressions and clinical significance of CD44v6 and CD44v8-10 in HER2 3+positive breast cancer.Methods This study included patients with HER2 IHC3+breast cancer undergoing neoadjuvant treatment and surgery who were diagnosed with core needle biopsy specimens from January 2019 to June 2022 in Dongguan City maternal&Child Health Hospital.Immunohistochemistry(IHC)was used to determine the expressions of CD44v6 and CD44v8-10.The correlations between CD44v6 or CD44v8-10 between HER2,estrogen receptor(ER)and progesterone receptor(PR)status,clinicopathological parameters and pathological complete response(pCR)were analyzed.Results The average age of the 86 cases with HER2 3+cases was(46.99±10.01)years.All cases showed a heterogeneous expression pattern of the CD44v6 and CD44v8-10,55(64.0%)cases with CD44v6 high expression and 58(67.4%)with CD44v8-10 high expression.Patients with high CD44v6 tumors had a significantly higher ER(76.4%vs 48.4%,P=0.017),PR(78.2%vs 19.4%,P<0.001)and Ki67(81.8%vs 61.3%,P=0.043)rate than those with low CD44v6 tumors.Patients with high CD44v8-10 tumors had a significantly higher PR(70.7%vs 28.6%,P<0.001)and lymph node metastasis(72.4%vs 14.3%,P<0.001)rate than those with low CD44v8-10 tumors.Patients with low CD44v6 expression(54.8%vs 30.9%;P<0.001)or CD44v8-10 expression(71.4%vs 24.1%;P<0.001)showed higher pCR rate than high expressions,respectively.Multivariate analysis showed that patients with HER2 diffuse 3+and CD44v8-10 had lower pCR(OR=5.281,95%CI:1.346-20.718,P=0.017;OR=5.062,95%CI:1.232-20.799,P=0.024,respectively).Conclusion We demonstrate that CD44 isoforms heterogeneity can be associated with the malignant features in HER2 3+breast cancer.CD44v8-10 can be considered to predict the prognosis of HER2 diffuse 3+breast cancer.关键词
CD44/异构体/HER2/乳腺癌/预后Key words
CD44/isoforms/HER2/breast cancer/prognosis分类
医药卫生引用本文复制引用
唐诗,温珮琦,邓杰华,李凯恒,陈黛诗..CD44异构体在HER2 3+阳性乳腺癌中的表达及其与预后的关系[J].解放军医学院学报,2024,45(7):746-752,7.基金项目
国家自然科学基金项目(31801160) （31801160）
东莞市社会科技发展重点项目(202050715007202) （202050715007202）
